More like this
J&J Announces Plan to Spin Off DePuy Synthes
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United StatesJohnson & Johnson…
CONFIRMED90% CONFIDENCE344 days agoThe release is datelined "NEW BRUNSWICK, NJ, October 14, 2025 - Johnson & Johnson ... today announced the Company's intent to separate its Orthopaedics business"; it states no time of day (CNBC's[3] report was up at 6:29 a.m. EDT and J&J's X post at 6:40 a.m. EDT), so the pin is the all-day 14 October.Johnson & Johnson said it would separate its roughly $9.2 billion-a-year orthopaedics business into a standalone company called DePuy Synthes within 18 to 24 months, and named former Smith & Nephew chief Namal Nawana to run it.0.66Lilly Agrees to Acquire Merida Biosciences for Up to $2.875 Billion
CONFIRMED88% CONFIDENCE23 days agoThe release is datelined "INDIANAPOLIS and CAMBRIDGE, Mass., Aug. 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Merida".[1]Lilly agrees to buy Merida Biosciences, whose Phase 1 MER511 is built to destroy the autoantibodies behind Graves' disease and thyroid eye disease, for up to $2.875 billion in cash.$2.9B0.66J&J Proposes $5.5 Billion Deal to Settle 76,000 Ovarian Cancer Talc Claims
CONFIRMED82% CONFIDENCE58 days agoJ&J's release is datelined "New Brunswick, N.J. - JULY 27, 2026 - Johnson & Johnson (NYSE: JNJ[1]) ... today announced", and the copy filed as Exhibit 99.1 to its 8-K is marked "FOR RELEASE AT 6:15PM ET", 22:15 UTC in EDT.Johnson & Johnson announced a proposed resolution of its remaining ovarian talc litigation, about 76,000 claims, with a $5.5 billion commitment paid per claim - no more than $3 billion in 2027 and nothing more before 2028 - if at least 95% of claimants take part.$5.5B0.66Oshkosh Acquires Pierce Manufacturing for $156.9 Million
CONFIRMED85% CONFIDENCE30.0 years agoOshkosh's own SEC[3] Form 10-K states the company acquired Pierce's stock for cash on September 18, 1996.Oshkosh Truck Corporation bought fire apparatus builder Pierce Manufacturing outright, a deal that kicked off Oshkosh's diversification and set up Pierce to become the world's largest fire truck maker.0.64DePuy Synthes Separates From Johnson & Johnson
ESTIMATED71% CONFIDENCEin 281 daysJ&J's 10-Q for the quarter to 28 June 2026 targets "completion within 18 to 24 months after the initial announcement" of 14 October 2025 (mid-April to mid-October 2027), and CFO Joseph Wolk said in July that J&J "is on track for a mid-2027 separation" (Bloomberg); "mid-2027" is read as the middle of the year, 1 July 2027, which sits inside that window.[1]Johnson & Johnson's orthopaedics business is due to leave the group as DePuy Synthes - by tax-free spinoff or by sale, with Apollo in talks at about $20 billion - and J&J says it is on track for a mid-2027 separation.0.64J&J Enterprise Business Review (Investor Day)
SCHEDULED85% CONFIDENCEin 76 daysJ&J set the date itself: CFO Joseph Wolk said on the 15 July Q2 call "We look forward to sharing more on strategy, growth catalysts and a longer-term outlook at our Enterprise business review on December 8", and the source[1] reports he "expects to present stronger growth expectations at its Dec. 8 investor day"; no time or venue has been announced, so the pin sits at J&J's headquarters as an all-day date.Johnson & Johnson holds its first enterprise business review since December 2023, where CFO Joseph Wolk says it will set out growth above its 5% to 7% long-term target, with a clear line of sight to double digits by the end of the decade.0.64Abbott Completes Its Acquisition of Exact Sciences
CONFIRMED87% CONFIDENCE184 days agoThe release is datelined "ABBOTT PARK, Ill., March 23, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has completed the acquisition of Exact Sciences".[1]Abbott closed its $105-a-share cash purchase of Cologuard maker Exact Sciences, which became a wholly owned Abbott subsidiary; Exact Sciences shares last traded on Nasdaq on 20 March.0.64Apollo in Talks to Buy J&J's DePuy Synthes for About $20 Billion
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United States
CONFIRMED82% CONFIDENCE12 days agoThe disclosure is Bloomberg's report, dated "September 11, 2026" (Yahoo's[1][2][5] syndicated copy went up at 22:26 UTC and quotes Friday's closing share prices); Reuters' write-up the same evening says "Bloomberg News reported on Friday", and Quartz's 14 September story is a follow-up, so the pin is the all-day 11 September.Bloomberg reported that Apollo Global Management is in talks to buy DePuy Synthes, J&J's $9.3 billion-a-year orthopaedics unit, at a value close to $20 billion, with a deal possible within weeks though J&J could still spin the unit off instead.$20B0.63J&J Q2 2026 Results: $25.3B Sales, 2026 Outlook Raised
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United States
CONFIRMED83% CONFIDENCE70 days agoConfirmed by J&J's release dated "New Brunswick, N.J. (July 15, 2026)", which says it "will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time" (12:30 UTC; the edited transcript is stamped "JULY 15, 2026 / 12:30PM GMT").[1]Johnson & Johnson reported second-quarter sales of $25.3 billion, up 6.6%, and adjusted EPS of $2.90, and raised its 2026 outlook to about $101.1 billion in sales and $11.68 adjusted EPS at the midpoint.0.63J&J Third-Quarter 2026 Results and Investor Call
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United States
SCHEDULED73% CONFIDENCEin 20 daysScheduled by J&J's 31 August release: it "will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 13th to review third-quarter results" and "The press release will be available at approximately 6:45 a.m. (Eastern Time) the morning of the conference call"; 8:30 a.m. EDT is 12:30 UTC.[1]Johnson & Johnson releases its third-quarter 2026 results at about 6:45 a.m. Eastern on Tuesday 13 October and reviews them on an 8:30 a.m. investor call hosted by CEO Joaquin Duato and CFO Joseph Wolk.0.62J&J Signs a Drug-Pricing Deal With Trump and Joins TrumpRx
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United States
CONFIRMED86% CONFIDENCE258 days agoJ&J's release is datelined "New Brunswick, N.J. – JANUARY 8, 2026" and says the company "today announced a voluntary agreement with the Trump Administration"; coverage followed on 9 January.[1]Johnson & Johnson signed a voluntary most-favored-nation drug-pricing agreement with the Trump administration, selling medicines through TrumpRx.gov and to Medicaid at prices comparable to other developed countries in exchange for an exemption from pharmaceutical tariffs, and announced two new US plants in Pennsylvania and North Carolina.0.62Abbott Agrees to Buy Exact Sciences for $21 Billion
CONFIRMED86% CONFIDENCE307 days agoThe release is datelined "ABBOTT PARK, Ill., and MADISON, Wis., Nov. 20, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) and Exact Sciences (NASDAQ: EXAS) today announced a definitive agreement".[1]Abbott agreed to buy Cologuard maker Exact Sciences for $105 a share in cash, a total equity value of about $21 billion, to enter cancer screening and precision oncology diagnostics.$21B0.62
